NASDAQ:IPXL Impax Laboratories (IPXL) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free IPXL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$17.40▼$18.9550-Day Range$18.30▼$18.3052-Week Range$13.05▼$25.70Volume3.04 million shsAverage Volume945,265 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Impax Laboratories alerts: Email Address Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Impax Laboratories Stock (NASDAQ:IPXL)Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.Read More Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. IPXL Stock News HeadlinesSeptember 10, 2023 | investing.comImpax Sustainable Allocation Fund Investor Class (PAXWX)May 23, 2023 | seekingalpha.comKBLB Kraig Biocraft Laboratories, Inc.April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.May 11, 2023 | wsj.comFerozsons Laboratories Ltd.April 5, 2023 | wsj.comImpax Ellevate Global Women's Leadership Fund;Individual InvestorApril 3, 2023 | thestreet.comImpax Stock Hits New 52-Week High (IPXL)March 28, 2023 | financialpost.comImpax CEO Says Funds Have Run Out of 'Investible' Green AssetsSeptember 29, 2022 | investing.comMorepen Laboratories Ltd (MORL)April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.September 9, 2022 | fool.comAbbott Laboratories (NYSE: ABT)July 27, 2022 | thestreet.comClearside Biomedical Inc. NewsSee More Headlines Receive IPXL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Impax Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2017Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:IPXL CUSIP45256B10 CIK1003642 Webwww.impaxlabs.com Phone(908) 947-3120FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesChintu PatelCo-Chief Executive Officer & DirectorChirag K. PatelPresident & Co-Chief Executive Officer & DirectorAndrew S. BoyerExecutive Vice President-Commercial OperationsAnastasios G. KonidarisChief Financial Officer & Senior Vice PresidentNikita ShahChief Human Resources Officer & Senior VPKey CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPView All Competitors IPXL Stock Analysis - Frequently Asked Questions How were Impax Laboratories' earnings last quarter? Impax Laboratories, Inc. (NASDAQ:IPXL) posted its quarterly earnings data on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.03. The specialty pharmaceutical company had revenue of $206.40 million for the quarter, compared to the consensus estimate of $208.38 million. The firm's quarterly revenue was down 9.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.37 EPS. What other stocks do shareholders of Impax Laboratories own? Based on aggregate information from My MarketBeat watchlists, some companies that other Impax Laboratories investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), NovoCure (NVCR), BlackRock Capital Investment (BKCC), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Viper Energy (VNOM) and Roper Technologies (ROP). This page (NASDAQ:IPXL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Impax Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
